Prolongevity Medicine: Antagonic-Stress® Drug in Distress, Geriatrics, and Related Diseases. II. Clinical Review—2003

Authors


Address for correspondence: D. Riga, Department of Stress Research and Prophylaxis, “Al. Obregia” Clinical Hospital of Psychiatry, 10 Berceni Road, Sector 4, RO-041914 Bucharest 8, Romania. Voice: +40-21-461-0755; fax: +40-21-230-9579. d_s_riga@yahoo.com

Abstract

Abstract: Distress and senescence, their reciprocal aggravating-quickening connections, and their related pathologies have a large worldwide impact on healthcare systems in this new millennium. For this reason, Antagonic-Stress® (AS)—an advanced integrative therapy, with specific synergistic composition, and patented internationally—represents a significant strategy in health, aging, and longevity. Clinical research with AS proves the drug's efficacy in the management of distress (neurotic, stress-related, and affective disorders; behavioral syndromes associated with physiological disturbances and physical factors; mental and behavioral disorders due to psychoactive substance uses) and psychogeriatrics [organic, including symptomatic, mental disorders (OMD)]. Specific multiaxial psychopathological instruments and psychometric tests in multiple assessments used for gerontopsychiatry demonstrated strong improvements after AS administration in early-moderate stages of Alzheimer or vascular dementia, as well as in other OMD. In addition, comparative clinical studies evinced the superiority of AS (synergistic multitherapy) versus monotherapy [meclofenoxate (MF), piracetam (PA), pyritinol (PT), and nicergoline (NE), respectively]. These comparative clinical trials agreed closely with comparative preclinical research and confirmed AS synergistic homeostatic, adaptogenic, antioxidative, cerebrovascular, neurometabolic, and nootropic actions. Also, the AS protective actions against oxidative stress recommend this orthomolecular therapy in stress, aging, and free radical pathology.

Ancillary